Oracle Life Sciences AI Data Platform Unites Data and Agentic Intelligence to Accelerate Medical Breakthroughs and Drive Commercial Success

Go back to Oracle Life Sciences AI Data Platform Unites Data and Agentic Intelligence to Accelerate Medical Breakthroughs and Drive Commercial Success

Barclays Reiterates Overweight Rating on Oracle (ORCL)

February 2, 2026 9:24 AM EST

Barclays analyst Raimo Lenschow reiterated an Overweight rating and $310.00 price target on Oracle (NYSE: ORCL).

The analyst comments "We see ORCL shares higher post the proposed raise of $45-50bn (approx. 1/2 through equity/equity-linked issuances) of gross cash proceeds. The transactions alleviate... More